<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03959839</url>
  </required_header>
  <id_info>
    <org_study_id>DSETAMIS-2018</org_study_id>
    <nct_id>NCT03959839</nct_id>
  </id_info>
  <brief_title>Endoscopic Submucosal Dissection vs Local Laparoscopic Surgical Resection (TAMIS/TEO) in Early Rectal Neoplasias</brief_title>
  <acronym>DSETAMIS2018</acronym>
  <official_title>Endoscopic Submucosal Dissection Versus Local Laparoscopic Surgical Resection (Transanal Minimally Invasive Surgery [TAMIS] / Transanal Endoscopic Operation [TEO]) In Early Rectal Neoplasias. Multicentric and Randomized Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dr. Alberto Herreros de Tejada Echanojáuregui</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>SPANISH SOCIETY OF DIGESTIVE ENDOSCOPY</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Puerta de Hierro University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A multicenter non-inferiority randomized clinical trial to compare Endoscopic treatment (ESD)
      and Minimally Invasive Laparoscopic Local Surgical Treatment (TAMIS or TEO) for early rectal
      neoplastic lesions (adenoma &amp; T1CRC) Primary aim: To compare the long-term local recurrence
      rate (12 months after the procedure)

      Secondary aims:

      Compare en-bloq resection rate, R0 resection, time per procedure, short-term recurrence rate,
      safety (rate of complications), morbidity and cost-effectiveness analyses.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A multicenter non-inferiority randomized clinical trial is proposed to compare two types of
      treatment for early rectal neoplastic lesions. Study arms:

        1. Endoscopic treatment: Endoscopic Submucosal Dissection (ESD)

        2. Minimally invasive laparoscopic local surgical treatment: Transanal Minimally Invasive
           Surgery (TAMIS) or Transanal Endoscopic Operation (TEO).

      Aims:

      Primary aim: To compare the long-term local recurrence rate (12 months after the procedure)
      of rectal lesions after ESD vs Surgical treatment (TAMIS/TEO).

      Secondary aims: Both arms of the study are compared according to other efficacy-related
      variables (en-bloq resection rate, R0 resection, time per procedure, short-term recurrence
      rate [6 months]), safety (rate of complications), morbidity (comparing different specific
      indexes: Wexner index, EQ-5L-5D, etc) and cost-effectiveness analyses (QALY).

      Inclusion criteria:

        -  Patients older than 18 y/o

        -  Non-pedunculated rectal lesions (sessile 0-Is or flat 0-II) greater than 20 mm in
           diameter.

        -  The edges of the lesion should be more than 3 cm from the external anal margin and up to
           14 cm from it.

        -  Circumferential involvement &lt;50%

      Exclusion criteria:

        -  Patients who refuse to participate.

        -  Diagnosis of inflammatory bowel disease with rectal involvement.

        -  Pregnant.

        -  Anorectal fibrosis due to previous anorectal surgery.

        -  Lateral Spreading Lesions (LST classification) Granular Homogeneous type

        -  Lesions greater than 50 mm when there is suspicion of advanced histology (Kudo Vi
           superficial pattern).

        -  Rectal lesions of any size with high suspicion of deep submucosal invasion or
           locoregional lymph node involvement, either in the diagnostic colonoscopy (Kudo Vn crypt
           pattern, NICE 3 pattern, Sano IIIB pattern) or by complementary imaging tests (rectal
           EUS/Pelvic MRI)

        -  Existence of synchronous colorectal lesions that require other surgical treatment in any
           case.

      N-size estimation:

      Assuming a global rate of long-term local recurrence in rectal lesions treated by TAMIS/TEO
      or ESD of 2.5% (using the data available in the medical literature), considering a
      non-inferiority limit of 10%, power of 80% (Beta error 0.2, alpha error 0.05) and assuming a
      loss of patients during the follow-up around 10%, 34 patients per group are required.

      Follow-up and Information collect:

      The follow-up will be of 1 year from the date of the intervention and the visits in which the
      information to be analyzed will be collected are adjusted to the usual clinical practice.

      The data would be registered using the on-line database system for medical research RedCap.

      Other information:

      The entire protocol of this study has been approved by de Ethical Committee on Clinical
      Research of the Puerta de Hierro University Hospital.

      The study counts with a Civil Responsibility Insurance policy.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 1, 2019</start_date>
  <completion_date type="Anticipated">April 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">April 1, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>local recurrence rate</measure>
    <time_frame>12 months</time_frame>
    <description>presence of remaining neoplastic tissue in resection site</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>En-bloq resection rate</measure>
    <time_frame>1 hour</time_frame>
    <description>Single piece of resection specimen</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>R0 resection rate</measure>
    <time_frame>1 hour</time_frame>
    <description>Free margin of neoplastic tissue both laterally and deep</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time per procedure</measure>
    <time_frame>1 hour</time_frame>
    <description>The length of the procedure expressed in minutes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of hospital stay</measure>
    <time_frame>1 hour</time_frame>
    <description>Days of hospital stay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Early complications rate</measure>
    <time_frame>1 hour</time_frame>
    <description>Registration of any deviations on the normal postoperative period in the first 24 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Delayed complications rate</measure>
    <time_frame>1 hour</time_frame>
    <description>Registration of any deviations on the normal postoperative period after the first 24 hours and up to 30 days after the procedure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Morbidity</measure>
    <time_frame>12 months</time_frame>
    <description>Changes in patients' quality of life using validated scores (both, specific and non-specific)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cost-effectiveness analyses (QALY)</measure>
    <time_frame>12 months</time_frame>
    <description>Cost-effectiveness analyses usin QALYs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Short-term local recurrence rate</measure>
    <time_frame>6 months</time_frame>
    <description>Presence of remaining neoplastic tissue in resection site</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">68</enrollment>
  <condition>Rectal Neoplasms</condition>
  <arm_group>
    <arm_group_label>Endoscopic Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Rectal Endoscopic Submucosal Dissection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Minimally Invasive Laparoscopic Local Surgical Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Transanal Minimally Invasive Surgery (TAMIS) or Transanal Endoscopic Operation (TEO)</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>ESD</intervention_name>
    <description>Rectal Endoscopic Submucosal Dissection</description>
    <arm_group_label>Endoscopic Treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>TAMIS</intervention_name>
    <description>Transanal Minimally Invasive Surgery</description>
    <arm_group_label>Minimally Invasive Laparoscopic Local Surgical Treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>TEO</intervention_name>
    <description>Transanal Endoscopic Operation</description>
    <arm_group_label>Minimally Invasive Laparoscopic Local Surgical Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients older than 18 y/o

          -  Non-pedunculated rectal lesions (sessile 0-Is or flat 0-II) greater than 20 mm in
             diameter.

          -  The edges of the lesion should be more than 3 cm from the external anal margin and up
             to 14 cm from it.

          -  Circumferential involvement &lt;50%

        Exclusion Criteria:

          -  Patients who refuse to participate.

          -  Diagnosis of inflammatory bowel disease with rectal involvement.

          -  Pregnant.

          -  Anorectal fibrosis due to previous anorectal surgery.

          -  Lateral Spreading Lesions (LST classification) Granular Homogeneous type

          -  Lesions greater than 50 mm when there is suspicion of advanced histology (Kudo Vi
             superficial pattern).

          -  Rectal lesions of any size with high suspicion of deep submucosal invasion or
             locoregional lymph node involvement, either in the diagnostic colonoscopy (Kudo Vn pit
             pattern, NICE 3 pattern, Sano IIIB pattern) or by complementary imaging tests (rectal
             EUS/Pelvic MRI)

          -  Existence of synchronous colorectal lesions that require other surgical treatment in
             any case.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eduardo Albéniz, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Complejo Hospitalario de Navarra</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Diego de Frutos, MD</last_name>
    <phone>+34600826265</phone>
    <email>diegodefrutos@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Alberto Herreros de Tejada, MD, PhD</last_name>
    <email>alberto.herreros@salud.madrid.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital Universitario Marqués de Valdecilla</name>
      <address>
        <city>Santander</city>
        <state>Cantabria</state>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Álvaro Terán</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario HM Montepríncipe</name>
      <address>
        <city>Boadilla Del Monte</city>
        <state>Madrid</state>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Felipe Ramos</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Puerta de Hierro</name>
      <address>
        <city>Majadahonda</city>
        <state>Madrid</state>
        <zip>28222</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Diego de Frutos, MD</last_name>
      <phone>600826265</phone>
      <email>diegodefrutos@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital QuironSalud Málaga</name>
      <address>
        <city>Málaga</city>
        <state>Malaga</state>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Pedro Rosón, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario de Navarra</name>
      <address>
        <city>Pamplona</city>
        <state>Navarra</state>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Eduardo Albeniz, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital de Sant Joan Despí Moisès Broggi</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>David Barquero</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario Gregorio Marañón</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Oscar Nogales</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario 12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jose Carlos Marín</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>May 16, 2019</study_first_submitted>
  <study_first_submitted_qc>May 20, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 22, 2019</study_first_posted>
  <last_update_submitted>May 20, 2019</last_update_submitted>
  <last_update_submitted_qc>May 20, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 22, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Puerta de Hierro University Hospital</investigator_affiliation>
    <investigator_full_name>Dr. Alberto Herreros de Tejada Echanojáuregui</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Early Rectal Neoplasms</keyword>
  <keyword>ESD</keyword>
  <keyword>TAMIS</keyword>
  <keyword>TEO</keyword>
  <keyword>Recurrence</keyword>
  <keyword>R0</keyword>
  <keyword>Safety</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rectal Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

